Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $42.6252W HIGH $71.07
Volume
800.22 K
Value Traded
42.18 M
Short % Float
8.49%
Days to Cover
7.3
+9.29%Week
+14.73%1 Month
-2.11%3 Month
-2.4%6 Month
-4.21%5 Year
+174.29%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.52 B
EPS (TTM)
3.63
P/E Ratio
14.67
Ent. Value
4.56 B
Total Shares
47.36 M
Float Shares
46.68 M
Insiders
1.47%
Institutions
115.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
PBH Catalyst Timeline
Dated clinical, regulatory and corporate events for Prestige Consumer Healthcare Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Prestige Consumer Healthcare Inc.
108Total events
1Upcoming
35Tier-1 (high impact)
2010 to 2026Coverage
Event history 50
◆AcquisitionCorporate
Prestige Consumer Healthcare completes acquisition of Breathe Right brand
◆AcquisitionCorporate
Prestige to acquire Breathe Right portfolio from Foundation Consumer Healthcare
●Quarterly UpdateCorporate
Narrowed fiscal 2026 revenue outlook to approximately $1.1 billion
◆Timing GuidancePresentation
Expect supply improvements for Clear Eyes in coming quarters
eye caresource ↗
▼Supply DisruptionCMC / Inspection
Supply chain challenges in eye care products expected to persist through first half of fiscal 2025
eye caresource ↗
▲Quarterly UpdateCorporate
Prestige Consumer Healthcare reports record fiscal Q4 2025 revenue and earnings
▲Quarterly UpdateCorporate
Repurchased ~0.6 million shares for ~$40.2 million in first nine months of fiscal 2025
▲Quarterly UpdateCorporate
Reported Q1 Fiscal 2025 results with revenue of $267.1M, EPS of $0.98, and cash from operations of $54.8M
●Quarterly UpdateCorporate
Reported fiscal year 2024 revenue of $1,125.4 million and Q4 revenue of $277.0 million
▲Quarterly UpdateCorporate
Revised long-term leverage target to less than 3.0x; expect below 3.0x by fiscal year-end 2024
●Quarterly UpdateCorporate
Reaffirmed fiscal 2024 outlook: revenue $1,135-1,140M, EPS $4.27-4.32, FCF $240M+
▲Quarterly UpdateCorporate
Prestige Consumer Healthcare reports fiscal year 2023 revenue of $1,127.7M
●Quarterly UpdateCorporate
Updated fiscal 2023 guidance: revenue $1,120-1,122M, diluted EPS ~$4.18, free cash flow ~$220M
▲Quarterly UpdateCorporate
Raised full-year fiscal 2022 outlook: revenue >=$1,045M, adj. diluted EPS >=$3.90
▲AcquiredCorporate
Prestige Consumer Healthcare completes acquisition of TheraTears and other OTC brands from Akorn
▲Partnership / LicenseTheraTearsCorporate
Acquisition of TheraTears and other brands closed on July 1, 2021
eye caresource ↗
◆AcquisitionCorporate
Prestige enters definitive agreement to acquire TheraTears portfolio from Akorn for $230M
●Quarterly UpdateCorporate
Prestige Consumer Healthcare reports fiscal Q4 2020 and full-year results
◆Oral PresentationPresentation
Presentation at Raymond James Institutional Investors Conference
●Quarterly UpdateCorporate
Company provides fiscal 2019 guidance: revenue $985-$995M, adj. EPS $2.84-$2.92
Past FDA Catalysts and PDUFA Decisions
How PBH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2004-10-01 | Monistat 1 Combination Pack (miconazole nitrate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Prestige Consumer Healthcare Inc. is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PBH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zerillo JeffreyOfficer (Senior VP Operations) | Sell | -351 41,810 held | $52.28 | 05/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PBH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PBH for Q2 2026. | ||||
Ownership Trends
PBH Short Interest
Shares sold short, counted twice a month.
8.49%
Short % of Float
of tradable shares sold short
4.0M
Shares Sold Short
-14.7% vs prior count
7.3 High
Days to Cover
trading days of normal volume to buy every short share back
546.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PBH ranks across every disease it competes in
Competitive Position is a premium feature
See how PBH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPBH News
PBH▲ +7.6%today
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results
Prestige Consumer Healthcare reported Q2 fiscal 2027 revenue of $336.3 million, a 22.7% increase from the previous year. Adjusted diluted EPS rose to $1.13, reflecting strong brand performance and contributions from recent acquisitions. However, net income fell to $25.3 million, impacted by lower sales of Clear Eyes® and order timing issues. The company updated its revenue guidance to $1,280 to $1,290 million.
Read more →PBHPrestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results
Prestige Consumer Healthcare Inc. will release its fiscal 2027 second quarter earnings on November 5, 2026, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the results. Participants can join via webcast or phone, with a replay available for a week.
Read more →PBHPrestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
Prestige Consumer Healthcare Inc. will participate in the Barclays Global Consumer Conference on September 10, 2026. Ron Lombardi and Christine Sacco will lead a fireside chat at 12:45 p.m. ET. A live webcast will be available, with a replay option for later viewing.
Read more →PBHFootball Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test
A recent survey by DenTek reveals that 78% of football fans continue to think about the game after it ends, with many experiencing stress that affects their sleep. The survey highlights that 60% of fans find the football season stressful, with significant numbers reporting anxiety and teeth grinding. DenTek aims to raise awareness of these issues through their Football Stress Test initiative.
Read more →PBHPrestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference
Prestige Consumer Healthcare Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. CFO Christine Sacco and VP Phil Terpolilli will engage in a fireside chat. A live webcast will be available, with a replay option for those unable to attend.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
Prestige Consumer Healthcare reported Q1 revenue of $265.7 million, up 6.5% year-over-year. Adjusted diluted EPS reached $0.98, beating prior year results. The company raised its full-year revenue outlook to $1,290–$1,315 million. This guidance includes the recent Breathe Right and LaCorium acquisitions.
Read more →PBHPrestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date
Prestige Consumer Healthcare Inc. has finalized its acquisition of LaCorium Health for approximately $150 million. The company also priced a $400 million offering of senior notes due 2034, aimed at refinancing existing debt. Additionally, Prestige will report its first quarter fiscal 2027 earnings on August 6, 2026.
Read more →PBHPrestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes
Prestige Consumer Healthcare Inc. announced plans to offer $400 million in senior notes due 2034. The proceeds will be used to redeem existing 5.125% Senior Notes due 2028. The redemption is contingent upon completing the new offering. This move reflects the company's strategy to manage its debt effectively.
Read more →PBHPrestige Consumer Healthcare Inc Completes Acquisition of Breathe
Prestige Consumer Healthcare Inc. has finalized the acquisition of the Breathe Right brand and other assets from Foundation Consumer Healthcare for approximately $1.045 billion. This acquisition, first announced on March 20, 2026, positions Breathe Right as Prestige's largest brand and marks its expansion into a new category. The deal was financed through available cash and a new Term Loan B, highlighting Prestige's strategic growth in the consumer healthcare market.
Read more →PBHPrestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
Prestige Consumer Healthcare Inc. will participate in the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference on June 8, 2026. The event will include a fireside chat at 9:45 a.m. ET, with a live webcast available on the company's website. A replay will also be accessible after the event.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health
Prestige Consumer Healthcare Inc. reported its fiscal 2026 results, showcasing revenues of $1,088.7 million despite a 4.3% decline from the previous year. The company announced the acquisition of LaCorium Health for approximately $150 million, which is expected to enhance growth in the therapeutic skin care market. Adjusted diluted earnings per share reached $4.38, down from $4.52 a year prior. The outlook for fiscal 2027 suggests organic revenue growth between 1% and 3%, but challenges in the Eye Ear Care category and overall consumer stability remain concerns.
Read more →PBHM A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Safe Harbor Disclosure 2 This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigati
Prestige Brands recently announced the acquisition of Breathe Right, a leading brand in the nasal strips market, for $1.045 billion. This deal is projected to immediately enhance Prestige's revenue, margins, and free cash flow while aligning with its growth strategy. The acquisition is subject to regulatory approvals and includes a financing structure that will involve new debt, initially raising the company's leverage. However, Prestige aims for rapid deleveraging, positioning itself for long-term success in the consumer healthcare sector.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results
Prestige Consumer Healthcare Inc. reported its financial results for Q3 and the first nine months of fiscal 2026, with revenues of $283.4 million, slightly exceeding expectations but down from the previous year. The diluted earnings per share (EPS) was $0.97, lower than last year's $1.22, primarily due to decreased sales in the Eye Ear Care category. The company has repurchased approximately 0.8 million shares during the quarter and successfully completed the acquisition of Pillar5 Pharma. Looking ahead, Prestige has narrowed its fiscal 2026 revenue outlook to about $1.1 billion amid a challenging consumer environment.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results
Prestige Consumer Healthcare Inc. reported its second quarter and first half fiscal 2026 results, revealing revenues of $274.1 million for Q2, which was above expectations but down 3.4% from the previous year. The company's diluted EPS for Q2 was reported at $0.86, down slightly from $1.09 in the same quarter last year. The company remains focused on rebuilding supply chain capacity for its Clear Eyes product, while also updating its earnings per share outlook for fiscal 2026 to the higher end of the previous range. Despite challenges in the Eye Ear Care category due to supply issues, the firm continues to emphasize brand building and shareholder value enhancement.
Read more →PBH▼ -10%on this news
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results
Prestige Consumer Healthcare Inc. reported its first quarter results for fiscal 2026, revealing a revenue decline to $249.5 million, largely attributed to supply constraints affecting its Clear Eyes product. Although diluted earnings per share (EPS) rose 6% to $0.95, the company's overall performance was impacted by lower shipments and a revised revenue outlook. To address production issues, Prestige announced an acquisition of Pillar5 Pharma, aiming to improve its eye care supply capacity. The adjusted revenue outlook for fiscal 2026 is now between $1,100 and $1,115 million.
Read more →PBH▲ +6.9%on this news
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
Prestige Consumer Healthcare Inc. reported impressive financial results for fiscal year 2025, achieving record revenues of $1,137.8 million and a diluted EPS of $4.29. Q4 revenues reached $296.5 million, reflecting a 7.9% organic growth. While the company is optimistic about fiscal 2026, projecting organic revenue growth of 1-2%, it also anticipates challenges related to inflationary tariffs and supply limitations for certain products. Overall, the results demonstrate steady performance in a diverse market environment.
Read more →PBH▲ +14.8%on this news
Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook
Prestige Consumer Healthcare Inc. reported record third quarter results, achieving revenues of $290.3 million, which is a 2.7% increase from the previous year. The company's diluted earnings per share also rose by 15% to $1.22. They announced a raise in their full-year earnings outlook, facilitated by strong profitability and cash flow. However, performance was somewhat mitigated by declines in the Cough Cold category and challenges in meeting demand for their Clear Eyes product line.
Read more →PBHPrestige Consumer Healthcare Inc. Expands CFO Christine Sacco's Role to Include Chief Operating Officer Responsibilities
Prestige Consumer Healthcare Inc. has announced the expansion of Chief Financial Officer Christine Sacco's role to include Chief Operating Officer responsibilities. This change is effective immediately and is aimed at enhancing the execution of the company's strategic initiatives. Sacco, who has been CFO since 2016, has been instrumental in driving sales and earnings growth. Her extensive experience in both finance and supply chain management positions her well for this dual role.
Read more →PBHPrestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2025 Results Revenue of $283.8 Million in Q2, Ahead of Outlook Diluted EPS of $1.09 in Q2, Up 2% Versus Prior Year Net Cash Provided by Opera
Prestige Consumer Healthcare Inc. (NYSE: PBH) reported revenues of $283.8 million for the second quarter of fiscal 2025, slightly down from the prior year but ahead of expectations. The company's diluted EPS rose 2% from last year to $1.09, reflecting positive performance driven by international growth, despite challenges from Clear Eyes supply constraints. Prestige reaffirmed its full-year guidance, anticipating revenue and earnings growth in the latter half of the fiscal year, supported by strong cash flow and a focus on long-term brand growth.
Read more →About Prestige Consumer Healthcare Inc.
Headquarters660 WHITE PLAINS RD., TARRYTOWN, NY, 10591
BIOPHARMAWATCH ELITE PLUS
Trade the next PBH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime